WCP
BMY icon

Wick Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Wick Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$760K Buy
12,536
+1,271
+11% +$74.1K 0.14% 65
2025
Q4 		$608K Buy
+11,265
New +$542K 0.11% 79

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wick Capital Partners's BMY Position: Q1 2026 in Review

Wick Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2026, buying an estimated $74.1K and bringing the position to 12,536 shares worth $760K. The position accounts for 0.14% of the portfolio, ranked #65.

Wick Capital Partners first reported a position in BMY in Q4 2025 and has held it in 2 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Wick Capital Partners held 12,536 shares of Bristol-Myers Squibb worth $760K as of Q1 2026.
  • Wick Capital Partners bought 1,271 Bristol-Myers Squibb shares in Q1 2026, an estimated $74.1K.
  • Bristol-Myers Squibb made up 0.14% of Wick Capital Partners's portfolio in Q1 2026, its #65 holding.
  • Wick Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 2 quarters since.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Wick Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.